Exhibit 99.1 Baudax Bio Corporate Presentation January 2022 1


Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio’s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “goal,” “intend,” and “expect,” and similar expressions, as they relate to Baudax Bio or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Baudax Bio as of the date of publication on this internet site and are subject to a number of risks, uncertainties, and other factors that could cause Baudax Bio’s performance to differ materially from those expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, among other things, risks related to the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the commercial launch of ANJESO® or disruption in supply chain, Baudax Bio’s ability to maintain regulatory approval for ANJESO, Baudax Bio’s ability to successfully commercialize ANJESO; the acceptance of ANJESO by the medical community, including physicians, patients, health care providers and hospital formularies; Baudax Bio’s ability and that of Baudax Bio’s third party manufacturers to successfully scale-up the commercial manufacturing process for ANJESO, Baudax Bio’s ability to produce commercial supply in quantities and quality sufficient to satisfy market demand for ANJESO, Baudax Bio’s ability to raise future financing for continued product development, payment of milestones and ANJESO commercialization, Baudax Bio’s ability to pay its debt and satisfy conditions necessary to access future tranches of debt, Baudax Bio’s ability to comply with the financial and other covenants under its credit facility, Baudax Bio’s ability to manage costs and execute on its operational and budget plans, the accuracy of Baudax Bio’s estimates of the potential market for ANJESO, Baudax Bio’s ability to achieve its financial goals; Baudax Bio’s ability to maintain its listing on the Nasdaq Capital Market; and Baudax Bio’s ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection. These forward-looking statements should be considered together with the risks and uncertainties that may affect Baudax Bio’s business and future results included in Baudax Bio’s filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law. 2


Company Highlights • ANJESO® (meloxicam) injection – Only once daily, non-opioid, analgesic – Approved for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics – Significant potential commercial opportunity • Additional neuromuscular blocking agents (NMBs) and proprietary reversal agent pipeline candidates in clinical stage development for acute care settings • Baudax financial position – Cash, cash equivalents and short-term investments as of 9/30/21 : $25 Million • Experienced management team with significant commercial, development, and regulatory experience 3 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


Experienced Commercial Management & Launch Leadership Team Gerri Henwood – President and CEO Founded Recro Pharma (REPH), Auxilium Pharmaceuticals (AUXL – NASDAQ then Endo) and IBAH (NASDAQ then Omnicare); GSK Richard Casten – Chief Financial Officer 25 years diversified financial experience – Lupin Pharmaceuticals (LUPIN - NSE), Endo International (ENDP - NASDAQ), Campbell Soup Company (CPB - NYSE), Ernst & Young LLP Jyrki Mattila, MD, PhD –EVP, Business Development Over 30 years of Pharma executive leadership and business development experience -Lipocine, iCeutica, Auxilium, Orion Pharma Greg Gangemi – Chief Commercial Officer and Sr. Vice President Over 25 years of industry, launch and operations experience – Recro, Sepracor/Sunovion, Cubist, Ferring and Ocular Therapeutix Janeese Carter – Vice President, Marketing Over 15 years of marketing, market research, new business strategy, and sales – Recro Pharma, CSL Behring, Pfizer/Wyeth 4


Commercial Opportunity 5


ANJESO® (meloxicam) Injection: The First and Only Once-Daily, Non-Opioid, IV Analgesic Demonstrated COX-2 Preferential Once-daily IV Up to 24-hour Safety & Tolerability IV NSAID* push pain relief Efficacy in That can be Ready-to-use, no Evaluated in more orthopedic & soft incorporated into reconstitution or 1 than 1500 patients tissue procedures MMA protocols refrigeration 1. Data on file. Baudax Bio, Inc. *The mechanism of action of IV meloxicam, like other NSAIDs, is not completely understood, but involves inhibition of both COX-1 and COX-2 pathways. COX-1 = cyclooxygenase 1; COX-2 = cyclooxygenase 2; IV = intravenous; NSAID = nonsteroidal anti-inflammatory drug; MMA = multimodal analgesia 6 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


ANJESO® (meloxicam) injection Overview • Proprietary non-opioid, once daily IV injection • Incorporates Alkermes’ NanoCrystal® technology • Once daily, long-acting, preferential COX-2 inhibitor for moderate to severe acute pain • Commercial Launch ongoing - Q4 growth trend continues Q3’21 reported metrics*: – Total number of vials sold to all customers up 16% – Vials sold to existing hospitals up 11% – Vials sold to new ambulatory surgery centers up 66% – Significant September rebound and overall Q3 growth, in spite of July/August CV-19 Delta Impact • Orange Book Listed patents run until 2030 * Quarter over quarter metrics based on third quarter of 2021 compared to second quarter 2021 7 Please see Important Safety Information including BOXED WARNING at the end of presentation.


ANJESO® Evaluated in Three Phase 3 Studies ANJESO 30 a Study Population Placebo Primary Endpoint Outcome mg 31% greater pain reduction vs 1 Bunionectomy n=100 n=101 SPID48* placebo (p=0.0034) 17% greater pain reduction vs 2 Abdominoplasty n=110 n=109 SPID24* placebo (p=0.0145) Safety, including number of Safety study; multiple hard patients with adverse Adverse Events comparable to n=538 n=183 3 & soft tissue procedures events up to 28 days after placebo dosing *SPID (Sum of Pain Intensity Differences) is calculated by the sum of the difference between current pain and baseline pain at each post-dose time point. SPID48 = summed pain intensity difference from 0-48 hours, SPID24 = a summed pain intensity difference from 0-24 hours. All studies completed with efficacy, safety and opioid reduction data. 1. Pollak RA et al. Clin J Pain. 2018;34(10):918-926. 2. Singla N et al. Plast Reconstr Surg Glob Open. 2018;6:e1846. 3. Bergese SD et al. Clin Pharmacol Drug Dev. 2019;8(8) 1062-1072. 8 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


ANJESO® Adverse Events Across All Phase 3 Studies Adverse Reactions in Placebo-Controlled Phase 3 ANJESO 30 mg Placebo Clinical Trials occurring in ≥2% of Patients Treated (n=748) (n=393) with ANJESO® and at a greater frequency than Placebo % (n) % (n) Constipation 57 (7.6%) 24 (6.1%) Gamma-Glutamyl Transferase Increased 21 (2.8%) 6 (1.5%) ANJESO (n=748) Anemia 18 (2.4%) 4 (1.0%) Source: ANJESO Prescribing Information 9 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


Two Phase 3b Health Economic Studies Completed with Preoperative Administration of ANJESO® Selection of ANJESO® Primary 1 2 Study Population Placebo Secondary Selection of Results 30 mg Endpoint Endpoints Evaluate efficacy of Preoperative administration of Evaluate impact on preoperative* ANJESO as part of a MMA regimen was Total Knee pain control and Arthroplasty n=93 n=88 administration associated with lower total mean hospital costs healthcare resource (TKA) measured by total >$2,500 during the hospital stay than patients in utilization opioid consumption the placebo group Evaluate impact on Evaluate safety and Preoperative administration of hospital LOS, opioid Bowel tolerability of ANJESO as part of a MMA regimen was well Resection n=27 n=28 consumption and preoperative* tolerated and decreased mean LOS by 1.1 days Surgery healthcare resource administration (3.6 vs 4.7 days) utilization *Preoperative dosing = ANJESO 30mg was administered prior to surgical incision (TKA) or 30 minutes prior to the start of surgery (bowel resection), then once-daily while in hospital until discharge or IV analgesic was no longer appropriate. 1. Studies completed with efficacy, safety, opioid reduction and healthcare resource utilization measures. 2. Data on file. Baudax Bio, Inc. Abstracts and publications pending. MMA = multimodal analgesia; LOS = length of stay 10 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


ANJESO® (meloxicam) Injection: The First and Only Once-Daily IV Analgesic Dosing and Administration Highlights • Once-daily, IV bolus injection over 15 seconds • Administered as a 30-mg (1 mL) dose • Available in a small* single dose vial • Ready-to-use • No reconstitution required • Room temperature storage – no need to refrigerate When initiating ANJESO, monitor patient analgesic response. Because the median time to meaningful pain relief was 2 and 3 hours after ANJESO administration in two clinical studies, a non-NSAID analgesic with a rapid onset of effect may be needed, for example, upon anesthetic emergence or resolution of local or regional anesthetic blocks. Source: ANJESO Prescribing Information. Some patients may not experience adequate analgesia for the entire 24-hour dosing interval and may require administration of a *Vial size approximately 16 X 34.5 mm short-acting, non-NSAID, immediate-release analgesic. 11 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


Commercial Update 12


Executive Summary Innovative Roles Anticipated Fast are Driving Growth Start for 2022 13


Q4 Targeted Efforts Focused on Closing 2021 Tele-sales Field Sales Targeting Driving awareness and adoption 90% Hyper Target Reach Expanded reach to over 400 new ASCS 70% Reach on Formulary Target Accounts 5 accounts “On Formulary” . Strong Congress Presence Peer to Peer Programs > 100 in completed in 2021 AAHKS, ASA, Painweek, ERAS, PGA, other local meetings 14


IQVIA NSP – Acute Care Launch Products 15


Sales continue to show quarter over quarter growth Estimated* Q4 Unit Sales growth has continued! Units Sold by Quarter 6,000 5,000 4,000 3,000 ~5,000 2,000 3,737 3,226 2,467 1,000 1,761 1,114 390 0 2Q'20 3Q'20 4Q'20 1Q'21 2Q'21 3Q'21 4Q'21 * Final reconciliation pending YE close analysis 16


Q4 Highlights Demonstrated Success Across Arenas • Surgical Hospital in the South-Central renewed • 5 Hospital Group accelerated growth growth with new Anesthesia practice joining • Top IDN early use around orthopedic • Top regional hospital adds ANJESO based and anesthesia service lines on clinical experience Regional IDNs Hospitals National ASCs ASC • Top 5 ASC Surgery centers (>125 sites) • Volume based Contacts performance Group national rollout lead by California • Approximately 10% penetration into • And Texas groups accounts within 1 month 17


Corporate Our Support Top-down Volume Based Strategic Agreement Approach To Direct Model Set- Up Large Accounts Sell Sheet Top-Down Communication and Education Create Account Awareness (touchpoints) Clinical Advocacy Champions Adoption Initial Orders Bottom-up 18


Preparing For 2022 19


Commercial Roles Work Closely Together Field Role Integration is Critical Internal team Tele-sales support Provides strategy, analysis, and support Traditional telesales supports field sales; to the business - expands reach Experienced Specialist telesales group operates standalone in unstaffed territories ACS leads in targeted accounts DNAs work top down Targets balance near, mid to longer-term Work in to engage C Suite and large IDN and account objectives to achieve sales goals. Chain Ambulatory Surgery Centers HEOR as formulary experts RBD as Player Coach Acts as team quarterback regionally Validate P&T Process Activity manages performance Critical for peer-to-peer exchange 20


Tailored Communication By Specialty Is Key To Increasing Likelihood To Trial Usage Evolving the Sophistication of our Messages Tailoring Launched with Phase 3B Data Highlighted real- Communication messages providing more world experience by Specialty to detailing Pivotal real-world, from current Address Specific Study data clinical data users Unmet Needs 21


Early Trial Accounts Are Opportunity To Expand Usage Advocacy is more than a surgeon Beyond the surgeon, cultivating those who support ANJESO onsite will Account Logistics build reliable and consistent usage and outcomes Expand usage Advocates Positive sustained experience allows broader intra account support with peers and across specialties Messaging ANJESO as a solution Positive clinical experience against specific patient type will drive reorders for advocate Targeting Teams stay focused on business plan targets Accelerate hyper targets and leverage HEOR to support P&T, pull through, and service line expansion 22


Investments in Execution Excellence in 2022 Fast Start Regional POA Meetings Roles & Best Integrity Selling Business Planning Practices Model for 1H’22 Ongoing Training Investments • Integrity Selling Follow-Up & Coaching • Micro-Learning Platform to Reinforce Key Messaging/Content • Surgical Profile Backgrounders • Phase II Training to bring tenured Reps into Home Office for continued reinforcement 23


Thank you! 24


Important Safety Information 25


Indication and Boxed Warning INDICATION ANJESO is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. Limitation of Use: Because of delayed onset of analgesia, ANJESO alone is not recommended for use when rapid onset of analgesia is required. IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Risk • Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. • ANJESO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. 26


Important Safety Information (cont) CONTRAINDICATIONS ANJESO is contraindicated in patients with: • Known hypersensitivity (eg, anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product. • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. • In the setting of coronary artery bypass graft (CABG) surgery. • Moderate to severe renal insufficiency patients who are at risk for renal failure due to volume depletion. WARNINGS AND PRECAUTIONS Hepatotoxicity: Elevations of ALT or AST have been reported in patients with NSAIDs. In addition, rare, sometimes fatal, cases of severe hepatic injury including fulminant hepatitis, liver necrosis, and hepatic failure have been reported. Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue ANJESO immediately if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop. Hypertension: NSAIDs including ANJESO can lead to new onset of hypertension or worsening of preexisting hypertension, which may contribute to the increased incidence of cardiovascular (CV) events. Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure. Heart Failure and Edema: NSAID use increased the risk of myocardial infarction (MI), hospitalization for heart failure, and death. Avoid use of ANJESO in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure. If ANJESO is used in patients with severe heart failure, monitor patients for signs of worsening heart failure. 27


Important Safety Information (cont) Post MI Patients: Avoid the use of ANJESO in patients with recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If ANJESO is used in these patients, monitor for signs of cardiac ischemia. Renal Toxicity: Long-term administration of NSAIDs has resulted in renal papillary necrosis, renal insufficiency, acute renal failure, and other renal injury. ANJESO is not recommended in patients with moderate to severe renal insufficiency and is contraindicated in patients with moderate to severe renal insufficiency who are at risk for renal failure due to volume depletion. Correct volume status in dehydrated or hypovolemic patients prior to initiating ANJESO. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of ANJESO in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function. If ANJESO is used in patients with advanced renal disease, monitor patients for signs of worsening renal function. Anaphylactic Reactions: Meloxicam has been associated with anaphylactic reactions in patients with and without known hypersensitivity to meloxicam and in patients with aspirin-sensitive asthma. Seek emergency help if an anaphylactic reaction occurs. Exacerbation of Asthma Related to Aspirin Sensitivity: ANJESO is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity). Serious Skin Reactions: NSAIDs, including ANJESO, can cause serious skin reactions, including exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal and can occur without warning. Discontinue ANJESO at first appearance of skin rash or other signs of hypersensitivity. Hematologic Toxicity: Anemia has occurred in NSAID-treated patients. Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia. NSAIDs, including ANJESO, may increase the risk of bleeding events. Monitor patients for signs of bleeding. 28


Important Safety Information (cont) DRUG INTERACTIONS Drugs That Interfere With Hemostasis (eg, warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking ANJESO with drugs that interfere with hemostasis. Concomitant use of ANJESO and analgesic doses of aspirin is not generally recommended. Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with ANJESO may diminish the antihypertensive effect of these drugs. Monitor blood pressure. ACE Inhibitors and ARBs: Concomitant use with ANJESO in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high-risk patients, monitor for signs of worsening renal function. Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to ensure diuretic efficacy including antihypertensive effects. ADVERSE REACTIONS The most common adverse reactions in controlled clinical trials occurring in ≥2% of patients treated with ANJESO and at a greater frequency than placebo included: constipation, gamma-glutamyl transferase increased and anemia. USE IN SPECIFIC POPULATIONS Pregnancy: Use of NSAIDs during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs in pregnant women starting at 30 weeks gestation. Infertility: NSAIDs are associated with reversible infertility. Consider withdrawal of ANJESO in women who have trouble conceiving. Please see full Prescribing Information, including Boxed Warning, at www.baudaxbio.com. 29


APPENDIX: Additional information for ANJESO® 30


Surgical Setting Coding and Reimbursement Hospital Inpatient Hospital Outpatient Ambulatory Surgery Centers Medicare Medicare Medicare • Use J3490• Unique Code, C9059 • Unique Code, C9059 • Reimbursement bundled into (Injection, Meloxicam 1mg) (Injection, Meloxicam 1mg) DRG payment• Reimbursed at 80% of 95%• Reimbursed at 80% of 95% of AWP of AWP Commercial Commercial Commercial • Use J3490• Permanent J-code J1738 • Permanent J-code J1738 • Bundled and part of a effective 10/1/2020 effective 10/1/2020 • May be bundled with case rate• May be bundled with procedure or separately procedure or separately reimbursed based on the reimbursed based on the facility contract facility contract AWP=average wholesale price; DRG=diagnosis related group. Permanent J-code J1738 Injection, meloxicam, 1 mg“ effective 10/1/2020 and replaced all other codes 31 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com